X0306 4 2013-11-01 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532475 Goldberg Mark Alan 33 HAYDEN AVE LEXINGTON MA 02421 false true false false SVP,Medical&Regulatory Affairs Common Stock 2013-11-01 4 M false 7000 8.73 A 7267 D Common Stock 2013-11-01 4 S false 3695 49.61 D 3572 D Common Stock 2013-11-01 4 S false 3205 50.34 D 367 D Common Stock 2013-11-01 4 S false 100 51.04 D 267 D Stock Option (Right to Buy) 8.73 2013-11-01 4 M false 7000 0 D 2021-09-22 Common Stock 7000 74703 D The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2012. The Stock Option granted the reporting person an option to purchase 88,703 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 09/22/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $49.00 to $49.96 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $49.97 to $50.84 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Mark Goldberg, SVP,Medical&Regulatory Affairs 2013-11-04